@engineeringsupplies: كل عام وانتم بخير

المكتب الهندسي للتوريدات
المكتب الهندسي للتوريدات
Open In TikTok:
Region: EG
Friday 06 June 2025 12:48:55 GMT
119
5
0
0

Music

Download

Comments

There are no more comments for this video.
To see more videos from user @engineeringsupplies, please go to the Tikwm homepage.

Other Videos

🚨 COMPOUNDED TIRZEPATIDE RECALLS — OCTOBER 2026 Two separate FDA Class II recalls involving compounded tirzepatide due to a lack of assurance of sterility. ⚠️ RECALL #1: APOTHECARY PHARMA, LLC 📍 Cary, North Carolina (503B outsourcing facility) Medication: Tirzepatide Injection Strength: 18 mg/mL Vial size: 4 mL multidose vial NDC: 85091-001-18 FDA Recall #: D-0036-2027 Recall initiated: September 24, 2026 AFFECTED LOT NUMBERS (22): AP-202622, AP-202623, AP-202624, AP-202625, AP-202627, AP-202628, AP-202629, AP-202630, AP-202631, AP-202632, AP-202633, AP-202634, AP-202635, AP-202636, AP-202637, AP-202638, AP-202639, AP-202640, AP-202641, AP-202642, AP-202643, AP-202644. Beyond-use dates: October 7–November 26, 2026. ⚠️ RECALL #2: HOUSTON RX, LLC 📍 Houston, Texas (503A compounding pharmacy) Medication: Tirzepatide/Niacinamide Injection Strength: 20 mg/2 mg per mL Vial size: 2 mL FDA Recall #: D-0040-2027 Recall initiated: September 25, 2026 AFFECTED LOT NUMBER: TZN-080326-20/2-2 Beyond-use date: December 1, 2026. 🚨 Both recalls involve a lack of assurance of sterility. These recalls do NOT involve FDA-approved Mounjaro or Zepbound. If you use compounded tirzepatide, verify the source of your medication and check your lot number. If your medication is affected, do not use it. Contact your dispensing pharmacy or prescriber for guidance. Remember: The pharmacy dispensing your medication may not be the facility that originally compounded it. #TikTokCreatorSearchInsightsIncentive #compoundglp1 #MedicationRecall
🚨 COMPOUNDED TIRZEPATIDE RECALLS — OCTOBER 2026 Two separate FDA Class II recalls involving compounded tirzepatide due to a lack of assurance of sterility. ⚠️ RECALL #1: APOTHECARY PHARMA, LLC 📍 Cary, North Carolina (503B outsourcing facility) Medication: Tirzepatide Injection Strength: 18 mg/mL Vial size: 4 mL multidose vial NDC: 85091-001-18 FDA Recall #: D-0036-2027 Recall initiated: September 24, 2026 AFFECTED LOT NUMBERS (22): AP-202622, AP-202623, AP-202624, AP-202625, AP-202627, AP-202628, AP-202629, AP-202630, AP-202631, AP-202632, AP-202633, AP-202634, AP-202635, AP-202636, AP-202637, AP-202638, AP-202639, AP-202640, AP-202641, AP-202642, AP-202643, AP-202644. Beyond-use dates: October 7–November 26, 2026. ⚠️ RECALL #2: HOUSTON RX, LLC 📍 Houston, Texas (503A compounding pharmacy) Medication: Tirzepatide/Niacinamide Injection Strength: 20 mg/2 mg per mL Vial size: 2 mL FDA Recall #: D-0040-2027 Recall initiated: September 25, 2026 AFFECTED LOT NUMBER: TZN-080326-20/2-2 Beyond-use date: December 1, 2026. 🚨 Both recalls involve a lack of assurance of sterility. These recalls do NOT involve FDA-approved Mounjaro or Zepbound. If you use compounded tirzepatide, verify the source of your medication and check your lot number. If your medication is affected, do not use it. Contact your dispensing pharmacy or prescriber for guidance. Remember: The pharmacy dispensing your medication may not be the facility that originally compounded it. #TikTokCreatorSearchInsightsIncentive #compoundglp1 #MedicationRecall

About